Eyebrows have been raised over the first-quarter performance of Novartis AG's psoriasis blockbuster Cosentyx (secukinumab) but the company has stressed that the drug is making major advances as first-line therapy in dermatology but more strikingly in its rheumatology indications.
Although sales of $580m, up 35% on the like, year-earlier period, looks like a decent return, Cosentyx revenues were 9%...








